Hologic, Inc. (NASDAQ:HOLX) Director Sells $276,908.24 in Stock

Hologic, Inc. (NASDAQ:HOLX) Director Elaine Ullian sold 6,902 shares of the firm’s stock in a transaction dated Thursday, August 3rd. The stock was sold at an average price of $40.12, for a total transaction of $276,908.24. Following the completion of the sale, the director now directly owns 23,810 shares of the company’s stock, valued at approximately $955,257.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Elaine Ullian also recently made the following trade(s):

  • On Monday, July 3rd, Elaine Ullian sold 8,849 shares of Hologic stock. The stock was sold at an average price of $45.28, for a total transaction of $400,682.72.
  • On Friday, June 2nd, Elaine Ullian sold 8,938 shares of Hologic stock. The stock was sold at an average price of $43.99, for a total transaction of $393,182.62.

Shares of Hologic, Inc. (NASDAQ:HOLX) traded down 1.40% during trading on Friday, reaching $37.42. 3,632,428 shares of the company traded hands. The firm’s 50 day moving average price is $42.62 and its 200-day moving average price is $42.82. The company has a market capitalization of $10.50 billion, a price-to-earnings ratio of 13.94 and a beta of 0.90. Hologic, Inc. has a 52 week low of $35.15 and a 52 week high of $46.80.

Hologic (NASDAQ:HOLX) last posted its earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 EPS for the quarter, beating the Zacks’ consensus estimate of $0.49 by $0.01. The firm had revenue of $806.10 million for the quarter, compared to the consensus estimate of $799.70 million. Hologic had a net margin of 25.65% and a return on equity of 23.18%. The company’s revenue was up 12.4% on a year-over-year basis. During the same period last year, the firm posted $0.51 EPS. Equities analysts anticipate that Hologic, Inc. will post $2.01 EPS for the current fiscal year.

WARNING: This piece was first published by BNB Daily and is the property of of BNB Daily. If you are viewing this piece on another site, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.baseball-news-blog.com/2017/08/19/elaine-ullian-sells-6902-shares-of-hologic-inc-nasdaqholx-stock-updated.html.

Several analysts have issued reports on HOLX shares. Piper Jaffray Companies reissued a “buy” rating and issued a $51.00 price objective on shares of Hologic in a research note on Friday, July 14th. Stifel Nicolaus reissued a “buy” rating on shares of Hologic in a research note on Friday, July 14th. Needham & Company LLC reissued a “buy” rating on shares of Hologic in a research note on Tuesday, August 1st. BidaskClub downgraded shares of Hologic from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 25th. Finally, BTIG Research reissued a “buy” rating and issued a $47.00 price objective on shares of Hologic in a research note on Sunday, May 14th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and nine have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $48.64.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Stratos Wealth Partners LTD. increased its position in Hologic by 0.6% in the second quarter. Stratos Wealth Partners LTD. now owns 4,954 shares of the medical equipment provider’s stock worth $225,000 after buying an additional 30 shares during the period. Cleararc Capital Inc. increased its position in Hologic by 1.1% in the first quarter. Cleararc Capital Inc. now owns 6,843 shares of the medical equipment provider’s stock worth $291,000 after buying an additional 77 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its position in Hologic by 0.4% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 20,803 shares of the medical equipment provider’s stock worth $944,000 after buying an additional 85 shares during the period. Compton Capital Management Inc. RI increased its position in Hologic by 0.6% in the first quarter. Compton Capital Management Inc. RI now owns 16,810 shares of the medical equipment provider’s stock worth $715,000 after buying an additional 100 shares during the period. Finally, Symphony Asset Management LLC increased its position in Hologic by 0.4% in the second quarter. Symphony Asset Management LLC now owns 28,005 shares of the medical equipment provider’s stock worth $1,271,000 after buying an additional 108 shares during the period. 94.43% of the stock is currently owned by hedge funds and other institutional investors.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Insider Buying and Selling by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply